Please try another search
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Name | Age | Since | Title |
---|---|---|---|
Mary T. Szela | 58 | 2014 | Independent Director |
Dennis M. Lanfear | 66 | 2010 | Chairman, President & CEO |
Michael Ryan | - | 2023 | Director |
James M. Daly | 61 | 2016 | Member of Strategic Advisory Board |
Jill O’Donnell-Tormey | 67 | 2022 | Independent Director |
Michael Lee Ryan | - | 2023 | Director |
Daniel G. Welch | 65 | 2023 | Member of Strategic Advisory Board |
Angus C. Russell | 67 | 2023 | Member of Strategic Advisory Board |
Taofeek K. Owonikoko | - | 2022 | Member of Scientific Advisory Board |
J. Leighton Read | 72 | 2023 | Member of Strategic Advisory Board |
Christopher A. Hunter | - | 2023 | Member of Scientific Advisory Board |
John Stagg | - | 2023 | Member of Scientific Advisory Board |
Alexander Rudensky | - | - | Member of Scientific Advisory Board |
John Wherry | - | - | Member of Scientific Advisory Board |
Georgia L. Erbez | 57 | 2024 | Director |
Ali J. Satvat | 47 | 2014 | Independent Director |
Thomas Graeber | - | 2021 | Member of Scientific Advisory Board |
Mats L. Wahlstrom | 70 | 2012 | Lead Independent Director |
Mark D. Stolper | 53 | 2021 | Independent Director |
Charles W. Newton | 53 | 2022 | Independent Director |
Carl F. Ware | - | 2021 | Member of Scientific Advisory Board |
Kimberly J. Tzoumakas | 56 | 2020 | Independent Director |
Lee N. Newcomer | 72 | 2022 | Independent Director |
Theresa M. Lavallee | 58 | 2022 | Chief Development Officer & Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review